(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq: APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant. Venaxis has ...
(Date:5/23/2013)... 2013 Can economic incentives such as ... members of the public to increase their donations of ... Hopkins Carey Business School Assistant Professor Mario Macis ... a large body of recent research that supports their ... 2013, issue of Science that the World Health Organization ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
(Date:5/23/2013)... , May 23, 2013 Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season. ... will work to support awareness of umbilical cord blood ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3